This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, L.-F. Articles by Hwang, J. Search for Related Content PubMed PubMed Citation Articles by Wang, L.-F. Articles by Hwang, J.

Identification of Mutations at DNA Topoisomerase I Responsible for Camptothecin Resistance¹

Institute of Molecular Biology [L-F. W., C-Y. T., C-K. L., J-S. S., J. H.] and Institute of Biomedical Sciences, Academic Sinica, Nankang [J. W-P.], and Department of Biochemistry, Taipei Medical College [L-F. W.], Taipei, Taiwan 11529, Republic of China, and Medicine Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 [L. A. M., A. T. F.]

A camptothecin-resistant cell line that exhibits more than 600-fold resistance to camptothecin, designated CPT^R-2000, was established from mutagen-treated A2780 ovarian cancer cells. CPT^R-2000 cells also exhibit 3-fold resistance to a DNA minor groove-binding ligand Ho33342, a different class of mammalian DNA topoisomerase I inhibitors. However, CPT^R-2000 cells exhibit no cross-resistance toward drugs such as Adriamycin, amsacrine, vinblastine, and 4'-dimethyl-epipodophyllotoxin. The mRNA, protein levels, and enzyme-specific activity of DNA topoisomerase I are relatively the same in parental and CPT^R-2000 cells. However, unlike the DNA topoisomerase I activity of parental cells, which can be inhibited by camptothecin, that of CPT^R-2000 cells cannot. In addition, parental cells after camptothecin treatment results in a decrease in the level of DNA topoisomerase I, whereas CPT^R-2000 cells are insensitive to camptothecin treatment. These results suggested that the mechanism of camptothecin resistance is most likely due to a DNA topoisomerase I structural mutation. This notion is supported by DNA sequencing results confirming that DNA topoisomerase I of CPT^R-2000 is mutated at amino acid residues Gly⁷¹⁷ to Val and Thr⁷²⁹ to Ile. We also used the yeast system to examine the mutation(s) responsible for camptothecin resistance. Our results show that each single amino acid change results in partial resitance, and the double mutation gives a synergetic effect on camptothecin resistance. Because both mutation sites are near the catalytic active center, this observation raises the possibility that camptothecin may act at the vicinity of the catalytic active site of the enzyme-camptothecin-DNA complex.

¹ This study was supported by grants from the National Science Council, Academia Sinica, and the National Health Research Institute.

² To whom requests for reprints should be addressed. Phone: 8862-789-9217; Fax: 8862-782-6085.

Received 9/23/96. Accepted 2/20/97.

This article has been cited by other articles:

				J.-y. Lu, Y.-y. Lin, J. Qian, S.-c. Tao, J. Zhu, C. Pickart, and H. Zhu Functional Dissection of a HECT Ubiquitin E3 Ligase Mol. Cell. Proteomics, January 1, 2008; 7(1): 35 - 45. [Abstract] [Full Text] [PDF]

				P. Fiorani, R. J. D. Reid, A. Schepis, H. R. Jacquiau, H. Guo, P. Thimmaiah, P. Benedetti, and M.-A. Bjornsti The Deubiquitinating Enzyme Doa4p Protects Cells from DNA Topoisomerase I Poisons J. Biol. Chem., May 14, 2004; 279(20): 21271 - 21281. [Abstract] [Full Text] [PDF]

				J.-Y. Chang, J.-F. Liu, S.-H. Juang, T.-W. Liu, and L.-T. Chen Novel Mutation of Topoisomerase I in Rendering Cells Resistant to Camptothecin Cancer Res., July 1, 2002; 62(13): 3716 - 3721. [Abstract] [Full Text] [PDF]

				Y. Urasaki, G. S. Laco, P. Pourquier, Y. Takebayashi, G. Kohlhagen, C. Gioffre, H. Zhang, D. Chatterjee, P. Pantazis, and Y. Pommier Characterization of a Novel Topoisomerase I Mutation from a Camptothecin-resistant Human Prostate Cancer Cell Line Cancer Res., March 1, 2001; 61(5): 1964 - 1969. [Abstract] [Full Text]

				M. Brangi, T. Litman, M. Ciotti, K. Nishiyama, G. Kohlhagen, C. Takimoto, R. Robey, Y. Pommier, T. Fojo, and S. E. Bates Camptothecin Resistance: Role of the ATP-binding Cassette (ABC), Mitoxantrone-resistance Half-Transporter (MXR), and Potential for Glucuronidation in MXR-expressing Cells Cancer Res., December 1, 1999; 59(23): 5938 - 5946. [Abstract] [Full Text] [PDF]

				P. Fiorani, J. F. Amatruda, A. Silvestri, R. H. Butler, M.-A. Bjornsti, and P. Benedetti Domain Interactions Affecting Human DNA Topoisomerase I Catalysis and Camptothecin Sensitivity Mol. Pharmacol., December 1, 1999; 56(6): 1105 - 1115. [Abstract] [Full Text]

				H. Komatani, M. Morita, N. Sakaizumi, K. Fukasawa, E. Yoshida, A. Okura, T. Yoshinari, and S. Nishimura A New Mechanism of Acquisition of Drug Resistance by Partial Duplication of Topoisomerase I Cancer Res., June 1, 1999; 59(11): 2701 - 2708. [Abstract] [Full Text] [PDF]

				Q. Fu, S.-W. Kim, H.-X. Chen, S. Grill, and Y.-C. Cheng Degradation of Topoisomerase I Induced by Topoisomerase I Inhibitors Is Dependent on Inhibitor Structure but Independent of Cell Death Mol. Pharmacol., April 1, 1999; 55(4): 677 - 683. [Abstract] [Full Text]

				C. L. Hann, A. L. Carlberg, and M.-A. Bjornsti Intragenic Suppressors of Mutant DNA Topoisomerase I-induced Lethality Diminish Enzyme Binding of DNA J. Biol. Chem., November 20, 1998; 273(47): 31519 - 31527. [Abstract] [Full Text] [PDF]

				M. R. Redinbo, L. Stewart, P. Kuhn, J. J. Champoux, and W. G. Hol Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA Science, March 6, 1998; 279(5356): 1504 - 1513. [Abstract] [Full Text]

				R. F. Frohlich, S. Gude Hansen, M. Lisby, I. Grainge, O. Westergaard, M. Jayaram, and B. R. Knudsen Inhibition of Flp Recombinase by the Topoisomerase I-targeting Drugs, Camptothecin and NSC-314622 J. Biol. Chem., March 2, 2001; 276(10): 6993 - 6997. [Abstract] [Full Text] [PDF]